传统和新型利尿剂在各种疾病中的作用

IF 0.3 Q4 PHARMACOLOGY & PHARMACY Current Drug Therapy Pub Date : 2024-01-24 DOI:10.2174/0115748855282746231208072819
Nitika Yadav, Neelottama Kushwaha, S. Kushwaha, Priyank Yadav
{"title":"传统和新型利尿剂在各种疾病中的作用","authors":"Nitika Yadav, Neelottama Kushwaha, S. Kushwaha, Priyank Yadav","doi":"10.2174/0115748855282746231208072819","DOIUrl":null,"url":null,"abstract":"\n\nDiuretics are advised as the initial course of action for hypertension because they are successful in lowering hypervolemia and resolving electrolyte abnormalities. The most popular diuretics\nare included with their main characteristics in this summary. The primary line of treatment for common cardiovascular and non-cardiovascular diseases is diuretics. Patients with hypertension, oedema,\nheart failure, as well as a variety of renal disorders are frequently treated with conventional diuretics.\nThe usage of the various types of diuretics that are now licensed for therapeutic use generally has a\nfavourable risk/benefit ratio. Nevertheless, they are not without drawbacks. Pharmaceutical scientists\nhave thus been working to develop new drugs with an enhanced pharmacological profile. SGLT2\ninhibitors (sodium-glucose-linked cotransporter 2 inhibitors) have altered how hypoglycaemic medications are thought to affect heart failure. Despite the presence or absence of diabetes, the sodiumglucose-linked cotransporter subtype 2-inhibitor class, which was first developed as a therapy for\nT2DM (Type 2 Diabetes mellitus), has shown considerable promise in lowering cardiovascular risk,\nparticularly in relation to heart failure (HF) outcomes. The immediate and substantial improvements\nobserved in clinical studies do not appear to be attributable to the drug's fundamental mechanism,\nwhich involves inducing glycosuria and diuresis by blocking receptors in the renal nephron. Among\npatients with chronic heart failure and cirrhosis, hyponatremia is a risk factor for death.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of Conventional and Novel Classes of Diuretics in Various Diseases\",\"authors\":\"Nitika Yadav, Neelottama Kushwaha, S. Kushwaha, Priyank Yadav\",\"doi\":\"10.2174/0115748855282746231208072819\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nDiuretics are advised as the initial course of action for hypertension because they are successful in lowering hypervolemia and resolving electrolyte abnormalities. The most popular diuretics\\nare included with their main characteristics in this summary. The primary line of treatment for common cardiovascular and non-cardiovascular diseases is diuretics. Patients with hypertension, oedema,\\nheart failure, as well as a variety of renal disorders are frequently treated with conventional diuretics.\\nThe usage of the various types of diuretics that are now licensed for therapeutic use generally has a\\nfavourable risk/benefit ratio. Nevertheless, they are not without drawbacks. Pharmaceutical scientists\\nhave thus been working to develop new drugs with an enhanced pharmacological profile. SGLT2\\ninhibitors (sodium-glucose-linked cotransporter 2 inhibitors) have altered how hypoglycaemic medications are thought to affect heart failure. Despite the presence or absence of diabetes, the sodiumglucose-linked cotransporter subtype 2-inhibitor class, which was first developed as a therapy for\\nT2DM (Type 2 Diabetes mellitus), has shown considerable promise in lowering cardiovascular risk,\\nparticularly in relation to heart failure (HF) outcomes. The immediate and substantial improvements\\nobserved in clinical studies do not appear to be attributable to the drug's fundamental mechanism,\\nwhich involves inducing glycosuria and diuresis by blocking receptors in the renal nephron. Among\\npatients with chronic heart failure and cirrhosis, hyponatremia is a risk factor for death.\\n\",\"PeriodicalId\":11004,\"journal\":{\"name\":\"Current Drug Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748855282746231208072819\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748855282746231208072819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

建议将利尿剂作为高血压的初始治疗方案,因为它们能成功降低高血容量和解决电解质异常。本摘要列出了最常用的利尿剂及其主要特点。利尿剂是治疗常见心血管疾病和非心血管疾病的主要药物。高血压、水肿、心力衰竭以及各种肾脏疾病患者经常使用传统的利尿剂进行治疗。然而,它们也并非没有缺点。因此,医药科学家们一直在努力开发药理作用更强的新药。SGLT2抑制剂(钠-葡萄糖链式共转运体2抑制剂)改变了降糖药物对心力衰竭的影响。尽管存在或不存在糖尿病,但钠-葡萄糖连接共转运体亚型 2 抑制剂类药物最初是作为治疗 2 型糖尿病(T2DM)的药物而开发的,在降低心血管风险,尤其是心力衰竭(HF)预后方面已显示出相当大的前景。临床研究中观察到的立竿见影的实质性改善似乎并不归因于该药物的基本机制,即通过阻断肾小球中的受体诱导糖尿和利尿。在慢性心力衰竭和肝硬化患者中,低钠血症是导致死亡的一个危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Role of Conventional and Novel Classes of Diuretics in Various Diseases
Diuretics are advised as the initial course of action for hypertension because they are successful in lowering hypervolemia and resolving electrolyte abnormalities. The most popular diuretics are included with their main characteristics in this summary. The primary line of treatment for common cardiovascular and non-cardiovascular diseases is diuretics. Patients with hypertension, oedema, heart failure, as well as a variety of renal disorders are frequently treated with conventional diuretics. The usage of the various types of diuretics that are now licensed for therapeutic use generally has a favourable risk/benefit ratio. Nevertheless, they are not without drawbacks. Pharmaceutical scientists have thus been working to develop new drugs with an enhanced pharmacological profile. SGLT2 inhibitors (sodium-glucose-linked cotransporter 2 inhibitors) have altered how hypoglycaemic medications are thought to affect heart failure. Despite the presence or absence of diabetes, the sodiumglucose-linked cotransporter subtype 2-inhibitor class, which was first developed as a therapy for T2DM (Type 2 Diabetes mellitus), has shown considerable promise in lowering cardiovascular risk, particularly in relation to heart failure (HF) outcomes. The immediate and substantial improvements observed in clinical studies do not appear to be attributable to the drug's fundamental mechanism, which involves inducing glycosuria and diuresis by blocking receptors in the renal nephron. Among patients with chronic heart failure and cirrhosis, hyponatremia is a risk factor for death.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Drug Therapy
Current Drug Therapy PHARMACOLOGY & PHARMACY-
CiteScore
1.30
自引率
0.00%
发文量
50
期刊介绍: Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.
期刊最新文献
Revolutionizing Healthcare and Drug Discovery: The Impact of Artificial Intelligence on Pharmaceutical Development Advancements in Natural Alkaloid-Loaded Drug Delivery Systems for Enhanced Peptic Ulcer Treatment: A Review Internet of Healthcare Things Based Detection of EEG Epileptic Seizures: A Smart System Exploring the Potential of Pectin for Gastro Retentive Drug Delivery Systems: From Orchard to Drug Delivery Gold Nanoparticles: An Emerging Novel Technology for Targeted Delivery System for Site-Specific Diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1